{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"84.9","value":"2680"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"259"}],"units":"Participants"}],"title":"Induction Period"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"77.6","value":"3930"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"164"}],"units":"Participants"}],"title":"Consolidation Period"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"74.7","value":"5080"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"115"}],"units":"Participants"}],"title":"Continuation Period - Dose 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"74.7","value":"10200"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"115"}],"units":"Participants"}],"title":"Continuation Period - Dose 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"259"}],"units":"Participants"}],"description":"AUCss was assessed by population Pharmacokinetic (PK) analysis during Cycle 1 of each phase.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants who were randomized to receive quizartinib treatment regimen.","id":"OG000","title":"Quizartinib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Parameters were assessed in the PK Analyses set, which includes all participants in the Intent-to-Treat Analysis Set who received at least 1 dose of quizartinib and had at least 1 PK sample assessed.","reportingStatus":"POSTED","timeFrame":"Induction Cycle 1: Day 8, predose, 2-4 hours (hr) postdose on Days 8, 15, 21; Consolidation Cycle 1: Day 6, predose, 2-4 hr postdose on Days 6, 13, 19; Continuation Cycle 1: 2-4 hr postdose, Days 1, 8, 15; Cycle 2 Days 1 and 15 (each cycle, 28 days)","title":"Pharmacokinetic Parameter Area Under the Concentration Versus Time Curve at Steady State","type":"SECONDARY","unitOfMeasure":"nanogram/milliliter (ng/mL)"}